SUMMARY
Resistance to endocrine therapy in breast cancer is still an unresolved significant problem in oncological practice. At an early stage of the disease it develops in approximately 10 – 15 % of cases within 5 years and in 30 % after 15 years. Most patients with advanced metastatic disease develop resistance within 2 – 3 years after the start of hormone therapy. The growing possibilities of overcoming the resistance of tumor cells (including the blockade of CDK 4/6, PI3K/Akt/mTOR, receptor tyrosine kinases along with new selective estrogen receptor downregulators) are a reflection of the enormous development of knowledge in the field of molecular pathogenesis of breast cancer. Several of them are recommended in the latest guidelines of international oncology organizations.

Key words: breast cancer, endocrine therapy, endocrine resistance, overcoming of endocrine resistance.
Lek Obz, 2021, 70 (5): 173-179

Lukáš ŠEBESTA 1, Magdaléna JABLONICKÁ 2, Beata MLADOSIEVIČOVÁ 1

1 Oddelenie klinickej patofyziológie LF UK, Bratislava, vedúca oddelenia prof. MUDr. B. Mladosievičová, PhD.
2 Onkologická klinika SZU, FNsP F.D. Roosevelta, Banská Bystrica, prednosta MUDr. V. Malec, PhD.

Cite:
ŠEBESTA L., JABLONICKÁ M., MLADOSIEVIČOVÁ B.: New possibilities of overcoming the endocrine resistance in patients with breast cancer. Lek Obz, 2021, 70 (5): 173-179